- Ultragenyx Pharmaceutical reported that UK and European regulators have begun formal reviews of UX111, its gene therapy for ultra-rare Sanfilippo syndrome Type A. Senior leadership is also preparing to present at two major London healthcare conferences in November 2026.
- Management now indicates a potential path to sustained profitability by 2027, combining significant cost reductions and a strong cash position with an expanding gene therapy portfolio that includes FAYUVI, GENGLYCOS and UX111.
- This article examines how Ultragenyx Pharmaceutical’s focus on profitability, supported by UX111 regulatory developments, may influence the previous turnaround investment narrative.
Spot 19 high quality undiscovered gems that share Ultragenyx…







